Intrathecal administration of 4-aminopyridine in chronic spinal injured patients

Study design: Intrathecal administration of 4-aminopyridine (4-AP) in chronic spinal cord injured (SCI) patients.

Objective: To determine the safety and effects of intrathecal administration of 4-AP in a small population of chronic SCI patients.

Setting: The post anesthesia care unit of a tertiary care hospital.

Methods: Following animal mode studies to establish dosing safety, six subjects with chronic SCI were examined. In each subject, an intrathecal catheter was placed with the tip as close to

the lesion level as possible. 4-AP was infused at 5 μg/h for a period of 4–5 h. Vital signs were recorded and sensory-motor physical examinations and pain questionnaires were administered

for 24 h. In two patients, samples of cerebrospinal fluid for analysis were drawn from a second intrathecal catheter.

Results: No adverse systemic side effects were noted. One patient showed transient improvement in sensory function; two showed transient increases in spasticity; three showed transient

increases in cutaneomuscular reflexes and two showed an apparent small increase in volitional motor control. The concentration of 4-aminopyridine in the cerebrospinal fluid reached a peak of

163 ng/ml at 4 h in one subject and 122 ng/ml at 5 h in the other subject examined.

Conclusion: Intrathecal administration of 4-aminopyridine at a rate of 5 μg/h does not appear to cause adverse effects and may modify spinal cord function. This route of administration

allows local cerebrospinal fluid concentrations equivalent to those produced by maximum tolerable systemic doses, which require 1000 times more drug substance to be delivered to the subject

as a whole. Intrathecal administration offers the potential to focus therapeutic effects to the lesion site while minimizing systemic side effects.

Anyone you share the following link with will be able to read this content: